US Microcarriers Market Size Likely to Grow at a CAGR of 10.1% By 2035

Market Size and Growth

The U.S. market for microcarriers is estimated to have a market size of USD 0.7 billion in 2025 and increase to USD 1.9 billion in 2035 with an annual growth rate of 10.1% from 2026 to 2035.

US Microcarriers Market Revenue and Trends

It is expected that the US microcarriers market will record high growth rates throughout the period 2026-2035 owing to the growing application of large-scale cell culture technologies in biopharmaceutical production, regenerative medicine and cell-based research. Microcarriers are extensively utilized to assist the adhesion and proliferation of adherent cells within bioreactors to facilitate the effective manufacture of vaccines, monoclonal antibodies, viral vectors, and cell therapies.

The increase in the market revenue can be further facilitated by the increase in biologics production capacity, the increase in the number of investments in the development of cell and gene therapies, and the growth of the demand for scalable and high-yield solutions in cell culture. The existence of the major biopharmaceutical firms, contract development and manufacturing organizations (CDMOs), and sophisticated research institutions makes the US a prime microcarrier adoption market.

What are the Factors That Have a Significant Contribution to the Growth of the US microcarriers market?

The US microcarrier market is highly endorsed by the inclination to intensified bioprocessing and continuous manufacturing models in the biopharmaceutical industry. Microcarrier-based systems are slowly replacing the use of biologic and advanced therapy in the context of reducing time-to-market; however, within the limited facility space, manufacturers are also seeking to maximize cell yield using a microcarrier-based system by enhancing process consistency.

Another major factor is the increasing tendency of the pharmaceutical companies to outsource. Scalable cell culture platforms are being heavily invested in by the contract development and manufacturing organizations (CDMOs) in the US due to increasing demand by small and mid-sized biotech companies. Microcarriers allow flexibilization of production in multiple projects and are therefore the choice in multiproduct manufacturing settings.

Moreover, the regulatory focus on process standardization and reproducibility is increasing the pace of the adoption of microcarriers. Microcarriers provide more control over cell growth parameters and batch-to-batch reproducibility compared to conventional planar culture systems, and this is essential to regulatory approval. Ongoing development of carrier materials, surface chemistry and compatibility with automation systems is also enhancing their contribution to next-generation biomanufacturing in the US.

Segment Insight

By Product

Consumables held the largest market share of the U.S. microcarriers market as of 2025 due to their recurring use in cell culture and bioprocessing workflows across research and commercial manufacturing facilities. Microcarrier beads, surface-treated carriers, and coating materials are required for each production cycle, making them essential for continuous cell expansion. Ongoing improvements in material consistency, sterility, and regulatory compliance have strengthened their adoption (widely regarded by manufacturers as reliable consumables that support scalable and cost-efficient cell culture operations).

By Application

Biopharmaceutical production accounted for the dominant application share of the U.S. microcarriers market as of 2025 because of the increasing reliance on large-scale adherent cell culture for the manufacturing of biologics, vaccines, and advanced therapies.

Microcarriers play a vital role in enabling high-density cell growth within bioreactors, while advancements in single-use systems and intensified processing have enhanced production efficiency (making microcarriers a core component of modern biomanufacturing strategies).

By End Use

Pharmaceutical and biotechnology companies represented the leading end-use segment of the U.S. microcarriers market as of 2025 owing to their extensive investments in biologics development, cell and gene therapies, and vaccine production. These organizations depend on microcarriers to achieve reproducible, scalable cell expansion for both clinical and commercial manufacturing. Strong R&D pipelines and expanding in-house and outsourced production capacities have reinforced their market dominance (positioning microcarriers as strategic inputs for accelerated product development).

Report Scope

Recent Developments

• In May 2022, beadMATRIX was presented by denovoMATRIX GmbH, which is a pre-assembled microcarrier with an MSC-optimized surface coating that allows improved cell attachment and growth performance. The product can be used with shaker flasks, shaker bags, stir tanks, and vertical-wheel bioreactors. This introduction extended the microcarrier product line of the company and facilitated more uptake in both cell therapy and regenerative medicine product applications.

List of the prominent players in the US Microcarriers Market:

• Thermo Fisher Scientific

• Merck KGaA (MilliporeSigma)

• Cytiva (formerly part of GE Healthcare Life Sciences)

• Corning Incorporated

• Sartorius AG

• Lonza Group

• Eppendorf AG

• Pall Corporation

• STEMCELL Technologies

• Avantor

• Others

The US Microcarriers Market is segmented as follows:

By Product

• Consumables

• Media

• Reagents

• Equipment

By Application

• Biopharmaceutical production

• Vaccine production

• Therapeutics production

• Regenerative medicine

• Other

By End-user

• Pharmaceutical & biotechnology companies

• CROs & CMOs

• Academic & research institutes

• Cell banks